Mounjaro is a prescription medicine for weight management in eligible adults. It contains tirzepatide and is used with dietary and physical activity support. A useful comparison considers clinical suitability, ongoing dose costs and access to a prescriber when problems arise.
What Mounjaro does
Tirzepatide acts at two hormone receptors, GIP and GLP-1, involved in appetite and glucose regulation. The UK weight-management authorisation covers adults with an initial BMI of at least 30, or at least 27 with a weight-related health condition. Treatment sits alongside a reduced-calorie diet and increased physical activity. A BMI threshold describes the licensed population; it does not establish that a particular person should receive a prescription.
Before comparing providers, separate three questions: whether the medicine is suitable for your health, whether a service can support your treatment, and whether the continuing cost is affordable. A low introductory price can answer only part of the third question.
Sources: MHRA: MHRA authorises Mounjaro for weight management and weight loss
What the weight-loss evidence can tell you
In SURMOUNT-1, adults without diabetes received tirzepatide or placebo alongside lifestyle support for 72 weeks. Mean weight reductions were 15.0%, 19.5% and 20.9% with the 5, 10 and 15 mg groups, compared with 3.1% with placebo. These are group averages over a defined study period, not promised outcomes or a target to reach within the first month.
The later SURMOUNT-5 trial directly compared tirzepatide with semaglutide injections in adults without diabetes. Mean reductions were 20.2% and 13.7% at 72 weeks. That comparison used the doses and participants in that trial; it does not compare every current formulation or establish which medicine suits an individual. It also does not compare tirzepatide with Wegovy 7.2 mg or either tablet.
Sources: New England Journal of Medicine: SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity; New England Journal of Medicine: SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
A dose review is a clinical decision
The initial 2.5 mg dose introduces treatment. Later increases are spaced to allow assessment of response and tolerability. The adult dose ceiling is 15 mg weekly, but reaching it is not a requirement for successful treatment. The prescribing information names 5, 10 and 15 mg as maintenance doses. A price table should distinguish the prescribed strength from a provider's suggested ordering sequence.
For a useful review, record your dose dates, weight trend, symptoms and any difficulty eating or drinking. Add new medicines and missed doses. A short factual record gives the clinician more to work with than a judgement such as 'it is no longer working'. Do not make a dose change because a different pen is discounted or in stock.
Sources: Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: UK Summary of Product Characteristics; NICE: Prescribing, reviewing and stopping tirzepatide
Know which symptoms need attention
Digestive symptoms such as nausea, diarrhoea and vomiting can occur. Persistent symptoms deserve review, especially when they prevent normal drinking or eating. Severe, persistent abdominal pain, sometimes spreading to the back, needs urgent medical assessment because pancreatitis is a recognised risk. Call 999 for breathing difficulty or swelling of the tongue or throat suggesting a serious allergic reaction.
Tell the prescriber about previous pancreatitis, significant digestive problems, diabetes treatment and pregnancy plans. Tirzepatide can affect oral contraception: people using the pill need a non-oral method or additional barrier contraception for four weeks after starting and after every dose increase. Mention treatment before an operation or procedure involving sedation, including when the prescription was obtained privately.
Sources: Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: patient information leaflet; MHRA: GLP-1 medicines: strengthened warnings on acute pancreatitis; NHS: Anaphylaxis: emergency symptoms and action; MHRA: GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedation
Make the service work in everyday life
A KwikPen contains four prescribed weekly doses. Use the instructions supplied for that device and arrange an explanation if any step is unclear. Do not improvise a smaller dose by counting clicks, share a pen, or extract leftover liquid. Ask the pharmacy how to arrange needles, sharps disposal and storage advice, particularly before travelling or if a delivery arrives in an unexpected condition.
Plan the first reorder before you need it. Ask when a repeat assessment happens, how long a clinician takes to respond, and what happens if treatment is interrupted. Keep the dispensing label and the latest leaflet available. These practical details are easy to overlook while comparing prices, yet they determine whether you can follow the agreed plan reliably.
Sources: Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: patient information leaflet; General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online
Compare a course of care, not just a first pen
NHS access is more restricted than the marketing authorisation and is being introduced in stages in England. A private prescription does not automatically qualify someone for NHS continuation. Ask your local service about its current pathway; access arrangements differ across the UK.
For private treatment, compare the same strength, the same quantity and the same eligibility conditions. Write down the first payment and the expected repeat payment separately. Include delivery, consultation charges, needles where charged, and any subscription commitment. Ask what support is available between orders. A provider comparison is most useful after a clinician has established the treatment and dose being considered, because price cannot determine medical suitability.
Sources: NHS England: Weight management injections: NHS England patient information; NHS England: Interim commissioning guidance for tirzepatide; NICE: TA1026: Tirzepatide for managing overweight and obesity; General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online
Compare prices for your prescribed dose
The licensed adult starting dose is 2.5 mg weekly for four weeks, then 5 mg. Further increases require at least four weeks at the current dose. The adult maintenance doses are 5, 10 or 15 mg; the prescriber decides what is appropriate.
These are first-order price observations, not prescribing recommendations. Repeat costs and additional fees may differ.
Questions, answered.
Does everyone need 15 mg?
No. The prescriber chooses a dose using response, tolerability and the treatment plan. A higher available strength is not an instruction to increase.
Sources: Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: UK Summary of Product Characteristics
Can I switch from another injection using its milligram dose?
No. Milligrams of different medicines are not interchangeable. Your prescriber needs your current treatment history and must provide a specific switching plan.
Sources: Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: UK Summary of Product Characteristics; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics
Is this hub a clinical review of my treatment?
No. This is general editorial information with sources checked on 19 November 2026. Independent clinical review of this content is pending, and your own prescriber remains responsible for treatment decisions.
Sources & further reading
Original sources for this guide. Source checks are not independent clinical review.
- Mounjaro KwikPen: UK Summary of Product CharacteristicsEli Lilly / electronic medicines compendium · Accessed 19 November 2026
- Mounjaro KwikPen: patient information leafletEli Lilly / electronic medicines compendium · Accessed 19 November 2026
- MHRA authorises Mounjaro for weight management and weight lossMHRA · Accessed 19 November 2026
- SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine · Accessed 19 November 2026
- SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of ObesityNew England Journal of Medicine · Accessed 19 November 2026
- Prescribing, reviewing and stopping tirzepatideNICE · Accessed 19 November 2026
- GLP-1 medicines: strengthened warnings on acute pancreatitisMHRA · Accessed 19 November 2026
- Anaphylaxis: emergency symptoms and actionNHS · Accessed 19 November 2026
- GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedationMHRA · Accessed 19 November 2026
- Weight management injections: NHS England patient informationNHS England · Accessed 19 November 2026
- Interim commissioning guidance for tirzepatideNHS England · Accessed 19 November 2026
- TA1026: Tirzepatide for managing overweight and obesityNICE · Accessed 19 November 2026
- How to keep safe when getting medicines or treatment onlineGeneral Pharmaceutical Council and UK health organisations · Accessed 19 November 2026
- Wegovy FlexTouch: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
